REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

REVLIMID® (lenalidomide) can be used in all levels of renal function1

Since REVLIMID is primarily excreted unchanged by the kidney, adjustments to the starting dose of REVLIMID are recommended to provide appropriate drug exposure in patients with renal impairment.21

Dose Modifications Based on Levels of Renal Function

  • CrCl, creatinine clearance.

CrCl is widely used to estimate GFR.22

  • GFR is an appropriate measure of renal function
  • SCr alone is not a sufficient measure of renal function because age, gender, race, and body size also impact GFR


Cockcroft-Gault Equations for Male and Female Renal Function

  • A correction for lean or ideal body weight should be considered in certain conditions (e.g., elderly, obese, fluid overload) when body weight may not be indicative of SCr levels.

The initial months of therapy are a critical evaluation period.1

  • To evaluate and manage cytopenias
    • Monitor CBCs weekly for the first 8 weeks, and at least monthly thereafter
    • Dosing is continued or modified based on clinical and laboratory findings
    • G-CSF was permitted for patients in the del 5q MDS study who developed neutropenia or fever associated with neutropenia
  • To evaluate response
    • At least 3 months of treatment may be necessary to achieve an RBC transfusion benefit
    • 90% (99/148) of patients who achieved a transfusion benefit in the trial did so by the completion of the first 3 months on REVLIMID

Learn how to modify dose of REVLIMID in patients with hematologic toxicities.

How to Dose Modify